10-K: ChromaDex Amends Lease, Files Annual Report, and Updates Incentive Compensation Policy

ChromaDex Corporation amends a lease for office space, files its annual report on Form 10-K, and updates its incentive compensation recoupment policy.

Summary

• ChromaDex amended its Los Angeles office lease, resulting in a remeasurement of the right-of-use asset and lease liability.
• The company's annual report on Form 10-K for the fiscal year ended December 31, 2023, was filed, detailing financial performance and business activities.
• A new incentive compensation recoupment policy was adopted, applying to incentive compensation paid or awarded on or after October 2, 2023.
• The company's net sales grew by 16% in 2023, reaching approximately $83.6 million, with a compound annual growth rate of 13% over the past five years.
• The consumer products segment saw a 16% increase in sales, while the ingredients segment grew by 27%.
• The company's net loss for 2023 was approximately $4.9 million, an improvement from the $16.5 million loss in 2022.
• Working capital decreased from $13.5 million in 2022 to $9.5 million in 2023.
• The company has purchase commitments of approximately $15.9 million related to inventory and $3.7 million related to future minimum lease obligations.
• The company relies on a single supplier, W.R. Grace, for NR and a limited number of third-party suppliers for raw materials.
• The company has over 275 research partnerships with leading universities and research institutions around the world.

Sentiment

Score: 7

Explanation: The document shows positive trends in revenue growth and reduced losses, but also highlights risks related to supply chain, competition, and litigation. The overall sentiment is cautiously optimistic.

Positives

• The company experienced a significant increase in net sales, driven by growth in both consumer products and ingredients segments.
• The company's net loss improved substantially year-over-year, indicating progress towards profitability.
• The company has a strong research and development program with numerous partnerships.
• The company has a strong brand associated with scientific rigor and a dedication to enhancing consumer health.
• The company has expanded its distribution to over 100 countries through strategic partnerships.

Negatives

• The company relies on a single supplier for NR, which poses a risk to its supply chain.
• The company has a history of operating losses and may need additional financing.
• The company is involved in ongoing litigation with Elysium Health, which could be costly and disruptive.
• The company's working capital decreased from $13.5 million in 2022 to $9.5 million in 2023.
• The company has a significant amount of purchase obligations related to inventory and leases.

Risks

• The company's future success depends heavily on sales of its Tru Niagen product.
• The company faces strong competition in the health and wellness industry.
• The company's operating results may fluctuate significantly, making future results difficult to predict.
• The company is subject to various government regulations, and changes in these regulations could impact its business.
• The company's ability to protect its intellectual property is uncertain and may be inadequate.
• The company may be subject to product liability claims or class action litigation.
• The company's reliance on a single supplier for NR poses a significant risk to its supply chain.
• The company's business could be negatively impacted by cyber security incidents or threats.

Future Outlook

The company anticipates that its current unrestricted cash and cash equivalents and cash to be generated from net sales will be sufficient to meet its financial obligations as they become due over at least the next twelve months and beyond. However, the company may seek additional funds to support both its short-term and long-term operating objectives.

Management Comments

• The company believes that it has identified reliable sources and suppliers of ingredients, chemicals, phytochemicals, and reference materials.
• The company believes that its strategic manufacturing relationships mitigate capital investment and enable cost control.
• The company is dedicated to providing an environment where ChromaDex employees can have fulfilling careers, be happy, healthy and productive.

Industry Context

The global wellness industry market was approximately $5.6 trillion in 2022, and the global dietary supplements market size was estimated at $164 billion in 2022. ChromaDex is positioned as a leader in the emerging NAD+ space, which is a growing area of interest in the health and wellness industry.

Comparison to Industry Standards

• ChromaDex competes with Elysium Health, which offers a similar product, and other providers of NAD+ boosting supplements.
• The company also faces competition from other ingredient suppliers who may supply alternative ingredients with similar characteristics.
• In the analytical reference standards and services segment, the company competes within the standardization and quality testing niche.
• The company's 16% net sales growth in 2023 is above the projected 8.9% compound annual growth rate for the global dietary supplements market from 2022 to 2030.
• The company's gross margin of 60.8% is strong compared to industry averages, but specific benchmarks for the dietary supplement industry are not provided in the document.

Corporate Governance

Legal Proceedings

• The company is currently engaged in substantial and complex litigation with Elysium Health, Inc. and Elysium Health LLC.
• The company is also involved in legal proceedings related to patent infringement with Thorne Research, Inc.

Related Party Transactions

• A.S. Watson Group, a related party, accounted for approximately 15.4% of the company's net sales in 2023.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance, litigation, and potential need for additional financing.
• Employees may be impacted by changes in compensation policies and the company's overall performance.
• Customers may be impacted by the availability and pricing of the company's products.
• Suppliers may be impacted by the company's purchase commitments and supply chain management.
• Creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will continue to focus on obtaining additional regulatory approvals to expand marketing and distribution of the Tru Niagen brand in new strategic international markets.
• The company will continue to monitor changing prices and inflationary pressures closely.
• The company will continue to work with its suppliers and partners to develop more efficient manufacturing methods.
• The company will continue to pursue new partnerships and business opportunities to diversify its customer base.

Key Dates

Keywords

nicotinamide riboside, Tru Niagen, NAD+, dietary supplements, healthy aging, bioscience, ingredients, research and development, intellectual property, lease amendment, financial results, recoupment policy